tiprankstipranks
Canton Strategic Holdings (CNTN)
NASDAQ:CNTN
US Market
Want to see CNTN full AI Analyst Report?

Canton Strategic Holdings (CNTN) AI Stock Analysis

226 Followers

Top Page

CNTN

Canton Strategic Holdings

(NASDAQ:CNTN)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - Gpt-5.6Sol)
Rating:48Neutral
Price Target:
$2.00
▼(-10.31% Downside)
Action:Reiterated
Date:08/19/26
Overall score reflects a strong, low-leverage balance sheet but is weighed down by very weak profitability and ongoing negative operating/free cash flow. Technicals also point to a bearish longer-term trend, while corporate actions (notably the $50M buyback) provide a modest offset.
Positive Factors
Debt-Free Balance Sheet
Zero debt and substantial equity provide financial flexibility and reduce interest and refinancing risk. This capitalization can help Canton fund strategic initiatives or absorb volatility while it works to establish a sustainable operating model.
Negative Factors
Severe Profitability Weakness
The very small revenue base relative to large and expanding losses indicates that commercial scale has not yet been established. Persistent losses constrain internal reinvestment and make future progress dependent on successful execution or additional funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
Zero debt and substantial equity provide financial flexibility and reduce interest and refinancing risk. This capitalization can help Canton fund strategic initiatives or absorb volatility while it works to establish a sustainable operating model.
Read all positive factors

Canton Strategic Holdings (CNTN) vs. SPDR S&P 500 ETF (SPY)

Canton Strategic Holdings Business Overview & Revenue Model

Company Description
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fos...

Canton Strategic Holdings Financial Statement Overview

Summary
Financials are mixed but overall weak: the balance sheet is a clear strength with zero debt and substantial equity/assets, but profitability is deeply negative (TTM net income ~-98.1M on minimal TTM revenue ~1.5M) and cash flow remains negative (TTM operating/free cash flow ~-22.2M), indicating ongoing cash burn and funding risk.
Income Statement
9
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
BreakdownTTMMar 2026Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.50M0.000.000.000.000.00
Gross Profit1.50M0.000.000.000.000.00
EBITDA-87.67M-42.05M-12.21M-9.15M-6.65M-1.38M
Net Income-98.12M-35.92M-12.20M-9.32M-8.47M-2.21M
Balance Sheet
Total Assets564.57M519.15M3.72M10.95M6.69M621.68K
Cash, Cash Equivalents and Short-Term Investments37.24M17.03M3.56M10.94M6.51M4.36K
Total Debt0.000.000.000.000.002.17M
Total Liabilities109.67M121.22M2.41M1.82M1.14M5.31M
Stockholders Equity454.90M397.93M1.31M9.13M5.54M-4.68M
Cash Flow
Free Cash Flow-22.17M-93.70M-10.90M-7.30M-6.56M-1.09M
Operating Cash Flow-22.17M-16.13M-10.90M-7.30M-6.56M-1.09M
Investing Cash Flow-138.16M-77.57M0.000.000.000.00
Financing Cash Flow195.91M107.17M3.53M11.72M13.06M898.75K

Canton Strategic Holdings Risk Analysis

Canton Strategic Holdings disclosed 71 risk factors in its most recent earnings report. Canton Strategic Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Canton Strategic Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$95.71M-0.59-218.94%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
$583.75M-3.35-53.86%-7.24%
48
Neutral
$187.25M-1.41-29.54%75.98%
47
Neutral
$69.75M-61.63-29.56%4.36%-123.29%
46
Neutral
$39.91M-0.81-156.02%-95.74%-23.18%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CNTN
Canton Strategic Holdings
2.22
-3.73
-62.69%
CRVO
CervoMed
2.60
-7.02
-72.97%
CSBR
Champions Oncology
4.93
-1.87
-27.50%
PTHS
Pelthos Therapeutics
24.73
1.08
4.57%
ARTV
Artiva Biotherapeutics, Inc.
11.09
7.94
252.06%

Canton Strategic Holdings Corporate Events

Business Operations and StrategyFinancial DisclosuresM&A TransactionsRegulatory Filings and Compliance
Canton Strategic Completes Gravitas Divestiture, Refocuses Strategy
Neutral
Jul 23, 2026
On July 17, 2026, Canton Strategic Holdings completed the sale of all membership interests in Gravitas Life Sciences, its clinical-stage biotech subsidiary, to Gravitas Collective Corp., an entity affiliated with former company directors, followin...
Executive/Board ChangesShareholder Meetings
Canton Strategic Holdings Updates Board Governance Committees
Positive
Jul 17, 2026
On July 13, 2026, Canton Strategic Holdings, Inc. held its 2026 annual meeting of stockholders, where a quorum of 25,792,741 shares out of 77,122,584 outstanding common shares was represented in person or by proxy. All seven director nominees were...
Business Operations and StrategyStock Buyback
Canton Strategic Launches $50 Million Share Repurchase Program
Positive
Jun 16, 2026
On June 11, 2026, Canton Strategic Holdings’ board approved a new share repurchase program authorizing the buyback of up to $50 million of the company’s common stock, with the decision disclosed in a June 16, 2026 press release. The co...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2026